Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates

References

• Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In Knipes DM, Howley PM, eds. Fields Virology. Lippincott Williams & Wilkins, 2007:2701-72.
   Google Scholar
• Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192:1331-9; PMID:16170749; https://doi.org/10.1086/466529
   PubMed Web of Science ®Google Scholar
• Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-14; PMID:18094380; https://doi.org/10.1056/NEJMra064928
   PubMed Web of Science ®Google Scholar
• Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, Pellegrini C, Meloni F, Rampino T. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6:2356-64; PMID:16889599; https://doi.org/10.1111/j.1600-6143.2006.01488.x
   PubMed Web of Science ®Google Scholar
• Gabanti E, Lilleri D, Ripamonti F, Bruno F, Zelini P, Furione M, Colombo AA, Alessandrino EP, Gerna G. Reconstitution of human cytomegalovirus-specific CD4+ T cells is critical for control of virus reactivation in hematopoietic stem cell transplant recipients but does not prevent organ infection. Biol Blood Marrow Transplant 2015; 21:2192-202; PMID:26260678; https://doi.org/10.1016/j.bbmt.2015.08.002
   PubMed Web of Science ®Google Scholar
• Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA, Hahn G, Nelson JA, Myers RM, Shenk TE. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A 2003; 100:14976-81; PMID:14657367; https://doi.org/10.1073/pnas.2136652100
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-85; PMID:16147978; https://doi.org/10.1084/jem.20050882
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Simon CO, Seckert CK, Lemmermann N, Grzimek NK. Murine model of cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol 2008; 325:315-31; PMID:18637514
   PubMed Web of Science ®Google Scholar
• Simon CO, Holtappels R, Tervo HM, Bohm V, Daubner T, Oehrlein-Karpi SA, Kühnapfel B, Renzaho A, Strand D, Podlech J, et al. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 2006; 80:10436-56; PMID:16928768; https://doi.org/10.1128/JVI.01248-06
   PubMed Web of Science ®Google Scholar
• Somogyi T, Michelson S, Masse MJ. Genomic location of a human cytomegalovirus protein with protein kinase activity (PK68). Virology 1990; 174:276-85; PMID:2152994; https://doi.org/10.1016/0042-6822(90)90075-3
   PubMed Web of Science ®Google Scholar
• Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci U S A 2003; 100:11439-44; PMID:12972646; https://doi.org/10.1073/pnas.1534570100
   PubMed Web of Science ®Google Scholar
• Zhu H, Shen Y, Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol 1995; 69:7960-70; PMID:7494309
   PubMed Web of Science ®Google Scholar
• Wilkinson GW, Kelly C, Sinclair JH, Rickards C. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. J Gen Virol 1998; 79(Pt 5):1233-45; PMID:9603339; https://doi.org/10.1099/0022-1317-79-5-1233
   PubMed Web of Science ®Google Scholar
• Gallina A, Percivalle E, Simoncini L, Revello MG, Gerna G, Milanesi G. Human cytomegalovirus pp65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals. J Gen Virol 1996; 77(Pt 6):1151-7; PMID:8683200; https://doi.org/10.1099/0022-1317-77-6-1151
   PubMed Web of Science ®Google Scholar
• Schmolke S, Drescher P, Jahn G, Plachter B. Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol 1995; 69:1071-8; PMID:7815485
   PubMed Web of Science ®Google Scholar
• Yao ZQ, Gallez-Hawkins G, Lomeli NA, Li X, Molinder KM, Diamond DJ, Zaia JA. Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting. Vaccine 2001; 19:1628-35; PMID:11166885; https://doi.org/10.1016/S0264-410X(00)00423-0
   PubMed Web of Science ®Google Scholar
• Pizzorno MC, Mullen MA, Chang YN, Hayward GS. The functionally active IE2 immediate-early regulatory protein of human cytomegalovirus is an 80-kgdalton polypeptide that contains two distinct activator domains and a duplicated nuclear localization signal. J Virol 1991; 65:3839-52; PMID:1645794
   PubMed Web of Science ®Google Scholar
• Delmas S, Martin L, Baron M, Nelson JA, Streblow DN, Davignon JL. Optimization of CD4+ T lymphocyte response to human cytomegalovirus nuclear IE1 protein through modifications of both size and cellular localization. J Immunol 2005; 175:6812-9; PMID:16272338; https://doi.org/10.4049/jimmunol.175.10.6812
   PubMed Web of Science ®Google Scholar
• Johnson RA, Yurochko AD, Poma EE, Zhu L, Huang ES. Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 protein-protein interaction and the possible functional consequences. J Gen Virol 1999; 80(Pt 5):1293-303; PMID:10355776; https://doi.org/10.1099/0022-1317-80-5-1293
   PubMed Web of Science ®Google Scholar
• Hagemeier C, Caswell R, Hayhurst G, Sinclair J, Kouzarides T. Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J 1994; 13:2897-903; PMID:8026474
   PubMed Web of Science ®Google Scholar
• Hsu CH, Chang MD, Tai KY, Yang YT, Wang PS, Chen CJ, Wang YH, Lee SC, Wu CW, Juan LJ. HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. EMBO J 2004; 23:2269-80; PMID:15141169; https://doi.org/10.1038/sj.emboj.7600239
   PubMed Web of Science ®Google Scholar
• Castillo JP, Kowalik TF. Human cytomegalovirus immediate early proteins and cell growth control. Gene 2002; 290:19-34; PMID:12062798; https://doi.org/10.1016/S0378-1119(02)00566-8
   PubMed Web of Science ®Google Scholar
• White EA, Spector DH. Exon 3 of the human cytomegalovirus major immediate-early region is required for efficient viral gene expression and for cellular cyclin modulation. J Virol 2005; 79:7438-52; PMID:15919900; https://doi.org/10.1128/JVI.79.12.7438-7452.2005
   PubMed Web of Science ®Google Scholar
• Macias MP, Stinski MF. An in vitro system for human cytomegalovirus immediate early 2 protein (IE2)-mediated site-dependent repression of transcription and direct binding of IE2 to the major immediate early promoter. Proc Natl Acad Sci U S A 1993; 90:707-11; PMID:8380646; https://doi.org/10.1073/pnas.90.2.707
   PubMed Web of Science ®Google Scholar
• Petrik DT, Schmitt KP, Stinski MF. The autoregulatory and transactivating functions of the human cytomegalovirus IE86 protein use independent mechanisms for promoter binding. J Virol 2007; 81:5807-18; PMID:17376893; https://doi.org/10.1128/JVI.02437-06
   PubMed Web of Science ®Google Scholar
• Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006; 80:1688-99; PMID:16439526; https://doi.org/10.1128/JVI.80.4.1688-1699.2006
   PubMed Web of Science ®Google Scholar
• Maul GG. Initiation of cytomegalovirus infection at ND10. Curr Top Microbiol Immunol 2008; 325:117-32; PMID:18637503
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44; PMID:7675046; https://doi.org/10.1056/NEJM199510193331603
   PubMed Web of Science ®Google Scholar
• Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201:1031-6; PMID:15795239; https://doi.org/10.1084/jem.20042384
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5; PMID:11797011; https://doi.org/10.1038/415331a
   PubMed Web of Science ®Google Scholar
• Hanke T. STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev Vaccines 2008; 7:303-9; PMID:18393600; https://doi.org/10.1586/14760584.7.3.303
   PubMed Web of Science ®Google Scholar
• Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005; 16:149-56; PMID:15761255; https://doi.org/10.1089/hum.2005.16.149
   PubMed Web of Science ®Google Scholar
• Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol 2009; 16:1285-92; PMID:19605598; https://doi.org/10.1128/CVI.00144-09
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, Chen M, Long R, McKelvey T, Chastain M, et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004; 78:11434-8; PMID:15452269; https://doi.org/10.1128/JVI.78.20.11434-11438.2004
   PubMed Web of Science ®Google Scholar
• Walsh MP, Seto J, Liu EB, Dehghan S, Hudson NR, Lukashev AN, Ivanova O, Chodosh J, Dyer DW, Jones MS, et al. Computational analysis of two species C human adenoviruses provides evidence of a novel virus. J Clin Microbiol 2011; 49:3482-90; PMID:21849694; https://doi.org/10.1128/JCM.00156-11
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950-7; PMID:19925902; https://doi.org/10.1016/j.vaccine.2009.10.145
   PubMed Web of Science ®Google Scholar
• Tang A, Li F, Freed DC, Finnefrock AC, Casimiro DR, Wang D, Fu TM. A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. Vaccine 2011; 29:8350-6; PMID:21888937; https://doi.org/10.1016/j.vaccine.2011.08.086
   PubMed Web of Science ®Google Scholar
• Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 2007; 45:20-7; PMID:17310936; https://doi.org/10.1097/QAI.0b013e3180377b5b
   PubMed Web of Science ®Google Scholar
• Fu TM, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol 1997; 71:2715-21; PMID:9060624
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies ME, Freed DC, Persaud NV, Dubey S, et al. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol 2002; 76:185-94; PMID:11739684; https://doi.org/10.1128/JVI.76.1.185-194.2002
   PubMed Web of Science ®Google Scholar